As the morbidity and mortality rate in acromegaly is significantly associated with IGF-1 and GH level, the aim of medical therapy is to ensure target IGF-1 level within age- and gender-specific normal ranges and to lower and normalize GH levels (1–4). This evidence concerns the gene GH1 and acromegaly.